Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New study tests addiction care to stop alcohol relapse after liver transplants

NCT ID NCT06472973

Disease control Sponsor: University Hospital, Montpellier Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at whether adding addiction counseling and monitoring after a liver transplant for alcohol-related liver disease can lower the chance of drinking again. About 720 adults who had a liver transplant for alcohol-related disease will be followed for two years. The goal is to see if this extra support helps people stay alcohol-free longer.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 720 people

The number the study aims to enrol. It can still change while the study runs.

Started

Nov 2024

Expected to finish

Nov 2030

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Aged 18 years or above * Hospitalized for LT for AALD as primary, secondary or tertiary indication * Discharged from intensive care unit to hepatology or surgery wards Exclusion Criteria: * Severe alcohol-associated hepatitis as primary indication for liver transplantation * Impossibility of patient follow up over the next 2 years * General criteria: * Refusal or absence of informed consent, * Non-affiliation to the French national health insurance, * Persons placed under legal protection, guardianship or curatorship

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Alcohol-associated liver disease are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

alcoholic liver disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Alcohol-associated liver disease Liver transplantation

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    16 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • APHP Mondor

    RECRUITING

    Paris, France

  • APHP Paul Brousse

    RECRUITING

    Paris, France

  • APHP Salpetrière

    RECRUITING

    Paris, France

  • Besançon University Hospital

    RECRUITING

    Besançon, France

  • Bordeaux University Hospital

    RECRUITING

    Bordeaux, France

  • Clermont Ferrand University Hospital

    RECRUITING

    Clermont-Ferrand, France

  • Dijon University Hospital

    RECRUITING

    Dijon, France

  • Lille University Hospital

    RECRUITING

    Lille, France

  • Lyon University Hospital

    RECRUITING

    Lyon, France

  • Marseille University Hospital

    RECRUITING

    Marseille, France

  • Montpellier University Hospital

    RECRUITING

    Montpellier, 34000, France

  • Nice University Hospital

    RECRUITING

    Nice, France

  • Rennes University Hospital

    RECRUITING

    Rennes, France

  • Strasbourg University Hospital

    RECRUITING

    Strasbourg, France

  • Toulouse University Hospital

    RECRUITING

    Toulouse, France

  • Tours University Hospital

    RECRUITING

    Tours, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.